Company Search:
Advanced Search
Sponsored Links
Genmab A/S Company Snapshot
Genmab A/S operates in the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other miscellaneous service companies in Europe: AddLife AB of SWEDEN (2019 sales of 3.48 billion Swedish Kronor [US$408.90 million] of which 57% was LabTech), Galapagos NV of BELGIUM (895.89 million Euros [US$1.07 billion] of which 93% was R&D), and Genus plc which is based in UNITED KINGDOM (£488.50 million [US$652.20 million] of which 52% was Operating Genus PIC).

Sales Analysis. Genmab A/S reported sales of 5.37 billion Danish Kroner (US$860.76 million) for the year ending December of 2019. This represents an increase of 77.4% versus 2018, when the company's sales were 3.03 billion Danish Kroner. Sales at Genmab A/S have increased during each of the previous five years (and since 2014, sales have increased a total of 531%).
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Genmab A/S
  Stock Performance Chart for Genmab A/S
  Stock Data: Recent Stock Performance:
  Current Price (11/27/2020): 2,319.00
(Figures in Danish Kroner)
1 Week 1.2%   13 Weeks 8.9%  
4 Weeks -0.4%   52 Weeks 46.8%  
Genmab A/S Key Data:
  Ticker: GMAB Country: Denmark
  Exchanges: CPH Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2019 Sales 5,366,000,000
(Year Ending Jan 2020).
Employees: 548
  Currency: Danish Kroner Market Cap: 151,576,398,132
  Fiscal Yr Ends: December Shares Outstanding: 65,362,828
  Share Type: Stammaktie Closely Held Shares: 3,037,934
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.